Barclays PLC Mirati Therapeutics, Inc. Call Options Transaction History

Barclays PLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2023 Feb 15, 2024	BUY	$41.99 - $62.38 $314,925 - $467,850	7,500 New	7,500 $441,000
Q3 2021 Nov 09, 2021	BUY	$132.13 - $177.45 $409,603 - $550,095	3,100 Added 1550.0%	3,300 $584,000
Q1 2020 May 13, 2020	SELL	$69.78 - $116.21 $3.13 Million - $5.21 Million	-44,800 Reduced 99.56%	200 $15,000
Q3 2019 Nov 14, 2019	BUY	$77.91 - $109.6 $1.56 Million - $2.19 Million	20,000 Added 80.0%	45,000 $3.51 Million
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $13.4 Million - $23.6 Million	-225,171 Reduced 90.01%	25,000 $2.58 Million
Q1 2019 May 15, 2019	SELL	$43.65 - $78.95 $1.3 Million - $2.35 Million	-29,829 Reduced 10.65%	250,171 $18.3 Million
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $10.7 Million - $14.3 Million	227,400 Added 432.32%	280,000 $13.2 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $1.37 Million - $2.76 Million	52,600 New	52,600 $2.59 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.